HHS Secretary Alex Azar on Friday systematically attacked drug manufacturers’ criticisms of the Trump administration’s plan to implement international price referencing for prescription drugs in Medicare Part B, saying despite strong denunciations, he does not think drug makers will play a “game of chicken” and walk away. The Pharmaceutical Research and Manufacturers of America denounced the administration’s plan , saying it would deny beneficiaries access to drugs and discourage innovation. When asked about the risk that drug companies would refuse...